Neda Safarzadeh
Vice President, Head of Investor Relations, Public Relations, and Marketing
Replay available
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joe Payne
President and CEO
Alan Cohen
Chief Medical Officer
Dennis Mulroy
Chief Financial Officer
Lily Nosongo
Analyst, Lyric Partners
Pete Starvopoulos
Analyst, Cantor Fitzgerald
Juwan Kim
Analyst, Citigroup
Jay Gon
Analyst, William Blair
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arcturus Therapeutics Holdings Inc..
Replay transcript excerpt
WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a04164-d63c-7002-afac-fe5b5c42935b Created: 2026-08-27T04:05:24.060Z Duration: 2168.9993 Channels: 1 00:00:00.160 -- 00:00:03.199 Beyond The United States into the Eastern Mediterranean 00:00:03.199 -- 00:00:03.919 region. 00:00:04.560 -- 00:00:06.879 Israel and Turkey are geographies with a high 00:00:06.879 -- 00:00:10.080 prevalence of individuals with CF class one or 00:00:10.080 -- 00:00:11.280 null mutations, 00:00:11.679 -- 00:00:14.605 which will meaningfully support our recruitment efforts and 00:00:14.605 -- 00:00:16.204 efficiencies for this study. 00:00:16.845 -- 00:00:18.605 Unlike The United States, 00:00:21.244 -- 00:00:22.605 the The United United 00:00:28.125 -- 00:00:28.285 States, 00:00:30.180 -- 00:00:32.260 in our ARCT032 00:00:32.260 -- 00:00:35.060 study from Turkey and Israel, respectively. 00:00:36.260 -- 00:00:39.380 Clinical execution remains on schedule, and we are 00:00:39.380 -- 00:00:42.180 laser focused on generating the data needed to 00:00:42.180 -- 00:00:45.335 support the phase three decision expected in Q4 00:00:45.335 -- 00:00:46.614 twenty twenty six. 00:00:47.734 -- 00:00:50.375 Turning to our OTC deficiency program, 00:00:50.454 -- 00:00:51.495 ARCT-eight 00:00:51.495 -- 00:00:52.054 10. 00:00:52.614 -- 00:00:54.934 During the quarter, we completed enrollment of the 00:00:54.934 -- 00:00:57.894 ongoing phase two study, and all enrolled subjects 00:00:57.894 -- 00:00:59.414 completed study drug dosing. 00:01:00.220 -- 00:01:02.700 This is an important operational milestone 00:01:02.780 -- 00:01:05.580 and allows us to now focus on evaluating 00:01:05.580 -- 00:01:07.180 the supplementary data 00:01:07.260 -- 00:01:09.660 generated from the enrolled study population. 0...